This double-blinded, randomized, placebo-controlled, parallel-arm pilot trial (n=20) will investigate the efficacy of intravenous ketamine for emergency department treatment of suicidal ideation (SI) in adolescents.
Approximately 20% of Canadian adolescents experience SI, and suicide ranks as the second leading cause of death among Canadians aged 15-19 years. Despite this, there are currently no fast-acting treatments available for SI in adolescents. Ketamine, known for its use in sedation, has shown efficacy in rapidly reducing SI in adults. However, its effectiveness in adolescents remains unstudied. The primary objective of this trial is to determine the feasibility of using intravenous ketamine to reduce SI in adolescents visiting the pediatric emergency department.
Participants, aged 12 to 17 years, who present with moderate to severe SI, will be enrolled. The study will involve two groups: one receiving intravenous ketamine and the other receiving a placebo. The study will assess the proportion of eligible participants who complete the study protocol, along with various secondary outcomes such as changes in suicidal ideation severity and safety measures.
If successful, this study could significantly impact the treatment of adolescent mental health emergencies and potentially reduce ED visits and admissions. The trial is being conducted at the Children’s Hospital of Eastern Ontario, with a projected completion date of September 2024.
Trial Details
Trial Number
Sponsors & Collaborators
Children's Hospital of Eastern OntarioCHEO is a pediatric health center in Ottawa, Canada, providing specialized care for young patients, including medical, surgical, mental health, & rehabilitation services.